325 Results

People

  1. Lacouture
    Lacouture
  2. Kris
    Kris
  3. Hudis
    Hudis
  4. Motzer
    Motzer
  5. Saltz
    Saltz
  6. Seidman
    Seidman
  7. Heelan
    Heelan
  8. Kelsen
    Kelsen
  9. Ilson
    Ilson
  10. Norton
    Norton

Groups

  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)
  7. Dermatology Service (41)
  8. Dermatology (41)
  9. Hematologic Malignancies, Division of (36)
  10. Surgery (34)
  1. "alopecia"
Formats
  1. Journal Article (301)
  2. Review (14)
  3. Conference Paper (5)
  4. Research Letter (3)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)

More Groups

People
  1. Mario Lacouture (38)
  2. Mark Kris (20)
  3. Clifford Hudis (15)
  4. Andrew Seidman (14)
  5. Leonard Saltz (14)
  6. Robert Motzer (14)

More People

Years
  1. 2025 (7)
  2. 2024 (20)
  3. 2023 (16)
  4. 2022 (11)
  5. 2021 (11)
  6. 2020 (14)

More Years

Publications
  1. Journal of Clinical Oncology (33)
  2. Cancer (14)
  3. Lancet Oncology (13)
  4. Clinical Cancer Research (12)
  5. Investigational New Drugs (11)
  6. Gynecologic Oncology (10)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. American Society of Clinical Oncology (35)
  3. Springer (31)
  4. Elsevier Science, Inc. (20)
  5. Wiley Blackwell (20)
  6. Oxford University Press (19)

More Publishers

Results (325)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed Mycosis fungoides: SWOG 1108
    Journal Article

    Barr, P. M.; Li, H.; Spier, C.; Mahadevan, D.; LeBlanc, M.; Ul Haq, M.; Huber, B. D.; Flowers, C. R.; Wagner-Johnston, N. D.; Horwitz, S. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial
    Journal Article

    Ribas, A.; Puzanov, I.; Dummer, R.; Schadendorf, D.; Hamid, O.; Robert, C.; Hodi, F. S.; Schachter, J.; Pavlick, A. C.; Lewis, K. D.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Current management and treatment modalities for intramedullary spinal cord tumors
    Journal Article

    Juthani, R. G.; Bilsky, M. H.; Vogelbaum, M. A.
    Current Treatment Options in Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma
    Journal Article

    Ballester-Sánchez, R.; Pons-Llanas, O.; Candela-Juan, C.; Celada-Alvarez, F. J.; De Unamuno-Bustos, B.; Llavador-Ros, M.; Ballesta-Cuñat, A.; Barker, C. A.; Tormo-Mico, A.; Botella-Estrada, R.; more...
    Journal of Contemporary Brachytherapy (2015)

    Fulltext@MSK | Save
  • Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
    Journal Article

    Belum, V. R.; Washington, C.; Pratilas, C. A.; Sibaud, V.; Boralevi, F.; Lacouture, M. E.
    Pediatric Blood and Cancer (2015)

    Fulltext@MSK | Save
  • Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients
    Journal Article

    Yaeger, R.; Cercek, A.; O'Reilly, E. M.; Reidy, D. L.; Kemeny, N.; Wolinsky, T.; Capanu, M.; Gollub, M. J.; Rosen, N.; Berger, M. F.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
    Journal Article

    Swain, S. M.; Baselga, J.; Kim, S. B.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J. M.; Schneeweiss, A.; Heeson, S.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Evolution of CD30 as a target in Hodgkin lymphoma, mature t-cell lymphoma, and other lymphomas
    Journal Article

    Younes, A.
    Clinical Advances in Hematology & Oncology (2014)

    Fulltext@MSK | Save